SMS PHARMACEUTICALS LTD.

The investor presentation for SMS Pharmaceuticals Limited for the quarter ended June 30, 2026, reported a 6% year-over-year increase in revenue, reaching ₹207 crore. The gross margin remained above 45%, indicating structural improvements in unit economics, while the EBITDA margin was sustained at approximately 20%. The presentation highlighted an 8% increase in profit after tax (PAT) to ₹20 crore. Management noted the completion of four DMF/CEP filings and stated a goal of achieving ten filings by the end of FY27. A capital expenditure program of ₹280 crore is progressing as planned, with an infusion of up to ₹50 crore approved for its subsidiary, SMS Peptides Private Limited. The R&D team has expanded to 200 members, supporting the development of niche and high-value APIs and peptides. The document emphasized the company's diversified growth and strategic focus on R&D.

Management highlighted growth and strategic advancements in the presentation.